Allergy Therapeutics to resume US clinical development program

UK-based allergy immunotherapy specialist Allergy Therapeutics (LSE: AGY) shares were up 5.2% at 21.70 pence on this morning, after the said it would resume its US clinical program for Pollinex Quattro Grass (modified allergen tyrosine absorbate with monophosphoryl lipid A).

Allergy Thera said that, following productive discussions with the US Food and Drug Administration regarding the US clinical development of Pollinex Quattro Grass MATA MPL, the company has submitted its clinical trial protocols to the FDA. The trials are scheduled to start in September 2015.

Back in 2007, clinical studies of its Pollinex Quattro range of allergy vaccines were suspended by the US FDA while it investigates the occurrence of a rare adverse event, classified by the physician involved as "possibly relevant" to the study (The Pharma Letter July 2007).